Skip to main content

FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments

The approval comes one day after the departure of Billy Dunn, the FDA's head of neuroscience.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.